Methylation of SRD5A2 in the Blood as a Novel Biomarker to Predict Sensitivity to 5-ARI Treatment
April 2024
in “
The Journal of urology/The journal of urology
”
Studysummary In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on auajournals.org →